SCHEMBL25324455

SCHEMBL25324455

Cc1ncc(Br)c2c1cnn2C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 3/20 0.42
▸ CYP4F2 P78329 3/20 0.41
▸ CYP4A11 Q02928 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GAA P10253 1/20 0.36
▸ CYP2C19 P33261 1/20 0.35
▸ ATR Q13535 1/20 0.35
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ PDE1A P54750 1/20 0.33
▸ PDE1B Q01064 1/20 0.33
▸ PDE1C Q14123 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25319462 0.87 RET (0.41) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL30551537 0.87 RET (0.41) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL25323920 0.85 RET (0.48) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL25328103 0.81 RET (0.38) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL30860948 0.80 CYP4F2 (0.44) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL27228058 0.80 CYP4F2 (0.44) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL27215114 0.80 CYP4F2 (0.41) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL29705330 0.80 CYP4F2 (0.41) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL25795344 0.80 CYP4F2 (0.41) RETCYP4F2CYP4A11ALDH1A1POLB
SCHEMBL14903852 0.79 CYP4F2 (0.47) RETCYP4F2CYP4A11ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN RET 1025/4885CYP4F2 333/4885CYP4A11 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback